New hope to stop deadly clots in kidney patients
NCT ID NCT07404436
Summary
This study is testing if a newer blood thinner, rivaroxaban, is better than the standard drug warfarin at preventing dangerous blood clots in people with a specific kidney disease called idiopathic membranous nephropathy. It will enroll about 134 patients at high risk for clots but low risk for bleeding. Over six months, researchers will compare how many serious clots and bleeding events happen in each group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friedship Hospital
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.